.jpg)
Conference Menu
Pre-Conference Workshop Overview Day 1 Day 2 Distinguished Faculty Register PDF Download Hotel & Travel Sponsor Press Pass Request Brochure
Complimentary Whitepaper
Partnering Best Practices for R&D Project Teams William C. Ronco, Ph.D., President, Gathering Pace Consulting
Corporate Sponsors:


Corporate Support Sponsor:

Sponsoring Associations:
.jpg)
.jpg)

.jpg)
Sponsoring Organization:

Lead Sponsoring Publications:
.gif)
.jpg)
.jpg)
Sponsoring Publications:
.jpg)
.jpg)
.jpg)


.jpg)

.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)

.jpg)

Web Partners:
.jpg)
.jpg)
.jpg)
.jpg)
|
|
A New Way to Discover Innovative Medicine: Approach from the East
Li Chen, Ph.D., Chief Scientific Officer, Roche R&D Center (China) Ltd |
Aligning Business, Corporate, and International Tax Strategy
Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company
|
|
How to Balance Internal and External Resources to Provide DMPK Support for Drug Discovery in China
Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China
|
Building an Integrated Biomedical Institute for Innovative Medicine in China
Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
|
|
Drug Discovery R&D in China: From Functional Capacity Outsourcing to Integrative Partnership
Guoxin Zhu, Ph.D., Director, Discovery Chemistry Research & Technology, Eli Lilly & Company
|
Accelerate Oncology Clinical Development in Asia
Michael Shi, Ph.D., Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis
|
|
The Latest Insights from China into Translational Research for Cancer
Jun Ren, M.D., Ph.D., Clinical Trials Coordination, Peking University School of Oncology/Beijing Cancer Hospital
|
Strategic Planning for Clinical Development Operations in China: Legal and Regulatory Considerations
Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.
|
Three Days of Interactive Discussions, Case Studies, Break-out Roundtables, and Panels
- In-Licensing, Out-Licensing, and Risk Sharing: The China Landscape for Partnership Deals
- Interactions and Initiatives Taken for Drug Development Between China and the Rest of Asia: A Focus on Oncology
- Opportunities for Drug Discovery in China: Chemistry, Biology, Integrated Projects, & Traditional Chinese Medicine
- How to Conduct High Quality, Cost Effective GLP Safety Studies in China
- Strategic Planning for Clinical Development Operations in China
- Comparative Assessment of Regulatory Processes and Time Lines
- The Role of Academic Clinical Trials Units for Drug Development in Asia
- Business Model Case Studies: Real Challenges and Strategies to Harness R&D Capabilities in China
On-Demand Webinar: The Impact of the Covance-WuXi Joint Venture
Click here to Listen to a pre-recorded webinar hosted by CHI's sister company, Cambridge Healthtech Associates (CHA), that was held on July 2, 2008.
During this complimentary, online session the following was discussed:
- Why Covance and WuXi created this joint venture
- How it may change pricing, services, and speed of growth in the pharma services sector in China
- Implications on the competitive dynamics between providers (i.e. Bridge, WuXi, CRL-China,
Medicilon-MPI, government labs, etc).
For questions about this conference, contact:
Micah Lieberman
Conference Director, Pharmaceutical Strategy Series
Cambridge Healthtech Institute
Tel: +1 541.482.4709
E-mail: mlieberman@pharmaseries.com
For partnership and sponsorship opportunities, contact:
Arnold Wolfson
Manager, Business Development
Cambridge Healthtech Institute
Tel: +1 781.972.5431
E-mail: awolfson@healthtech.com
|
|
|